載入...
p53, HER2 and tumor cell apoptosis correlate with clinical outcome after neoadjuvant bevacizumab plus chemotherapy in breast cancer
Bevacizumab, an antibody to vascular endothelial growth factor (VEGF), has been incorporated into chemotherapy regimens in the treatment of several cancer types including breast cancer. The aim of this study was to identify tumor and angiogenic factors that potentially associate with outcome. In a p...
Na minha lista:
| 發表在: | Int J Oncol |
|---|---|
| Main Authors: | , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
2011
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7316373/ https://ncbi.nlm.nih.gov/pubmed/21399868 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/ijo.2011.966 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|